Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
10
10
2019
accepted:
28
04
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
11
8
2020
Statut:
epublish
Résumé
De novo lipogenesis (DNL) is the primary metabolic pathway synthesizing fatty acids from carbohydrates, protein, or alcohol. Our aim was to examine associations of in vivo levels of selected fatty acids (16:0, 16:1n7, 18:0, 18:1n9) in DNL with incidence of type 2 diabetes (T2D). Seventeen cohorts from 12 countries (7 from Europe, 7 from the United States, 1 from Australia, 1 from Taiwan; baseline years = 1970-1973 to 2006-2010) conducted harmonized individual-level analyses of associations of DNL-related fatty acids with incident T2D. In total, we evaluated 65,225 participants (mean ages = 52.3-75.5 years; % women = 20.4%-62.3% in 12 cohorts recruiting both sexes) and 15,383 incident cases of T2D over the 9-year follow-up on average. Cohort-specific association of each of 16:0, 16:1n7, 18:0, and 18:1n9 with incident T2D was estimated, adjusted for demographic factors, socioeconomic characteristics, alcohol, smoking, physical activity, dyslipidemia, hypertension, menopausal status, and adiposity. Cohort-specific associations were meta-analyzed with an inverse-variance-weighted approach. Each of the 4 fatty acids positively related to incident T2D. Relative risks (RRs) per cohort-specific range between midpoints of the top and bottom quintiles of fatty acid concentrations were 1.53 (1.41-1.66; p < 0.001) for 16:0, 1.40 (1.33-1.48; p < 0.001) for 16:1n-7, 1.14 (1.05-1.22; p = 0.001) for 18:0, and 1.16 (1.07-1.25; p < 0.001) for 18:1n9. Heterogeneity was seen across cohorts (I2 = 51.1%-73.1% for each fatty acid) but not explained by lipid fractions and global geographical regions. Further adjusted for triglycerides (and 16:0 when appropriate) to evaluate associations independent of overall DNL, the associations remained significant for 16:0, 16:1n7, and 18:0 but were attenuated for 18:1n9 (RR = 1.03, 95% confidence interval (CI) = 0.94-1.13). These findings had limitations in potential reverse causation and residual confounding by imprecisely measured or unmeasured factors. Concentrations of fatty acids in the DNL were positively associated with T2D incidence. Our findings support further work to investigate a possible role of DNL and individual fatty acids in the development of T2D.
Sections du résumé
BACKGROUND
De novo lipogenesis (DNL) is the primary metabolic pathway synthesizing fatty acids from carbohydrates, protein, or alcohol. Our aim was to examine associations of in vivo levels of selected fatty acids (16:0, 16:1n7, 18:0, 18:1n9) in DNL with incidence of type 2 diabetes (T2D).
METHODS AND FINDINGS
Seventeen cohorts from 12 countries (7 from Europe, 7 from the United States, 1 from Australia, 1 from Taiwan; baseline years = 1970-1973 to 2006-2010) conducted harmonized individual-level analyses of associations of DNL-related fatty acids with incident T2D. In total, we evaluated 65,225 participants (mean ages = 52.3-75.5 years; % women = 20.4%-62.3% in 12 cohorts recruiting both sexes) and 15,383 incident cases of T2D over the 9-year follow-up on average. Cohort-specific association of each of 16:0, 16:1n7, 18:0, and 18:1n9 with incident T2D was estimated, adjusted for demographic factors, socioeconomic characteristics, alcohol, smoking, physical activity, dyslipidemia, hypertension, menopausal status, and adiposity. Cohort-specific associations were meta-analyzed with an inverse-variance-weighted approach. Each of the 4 fatty acids positively related to incident T2D. Relative risks (RRs) per cohort-specific range between midpoints of the top and bottom quintiles of fatty acid concentrations were 1.53 (1.41-1.66; p < 0.001) for 16:0, 1.40 (1.33-1.48; p < 0.001) for 16:1n-7, 1.14 (1.05-1.22; p = 0.001) for 18:0, and 1.16 (1.07-1.25; p < 0.001) for 18:1n9. Heterogeneity was seen across cohorts (I2 = 51.1%-73.1% for each fatty acid) but not explained by lipid fractions and global geographical regions. Further adjusted for triglycerides (and 16:0 when appropriate) to evaluate associations independent of overall DNL, the associations remained significant for 16:0, 16:1n7, and 18:0 but were attenuated for 18:1n9 (RR = 1.03, 95% confidence interval (CI) = 0.94-1.13). These findings had limitations in potential reverse causation and residual confounding by imprecisely measured or unmeasured factors.
CONCLUSIONS
Concentrations of fatty acids in the DNL were positively associated with T2D incidence. Our findings support further work to investigate a possible role of DNL and individual fatty acids in the development of T2D.
Identifiants
pubmed: 32530938
doi: 10.1371/journal.pmed.1003102
pii: PMEDICINE-D-19-03743
pmc: PMC7292352
doi:
Substances chimiques
Fatty Acids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003102Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007703
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : N01 HC095162
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85082
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095165
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL085710
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095164
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095160
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095163
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85080
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG023629
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095168
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL080295
Pays : United States
Organisme : NIA NIH HHS
ID : N01 AG012100
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL076200
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL047892
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL130114
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095169
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55222
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85079
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00006/3
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : N01HC85083
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL047902
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095159
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85086
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095161
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK046200
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC025195
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01 HC095166
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL035464
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : Department of Health
ID : IS-BRC-1215-20014
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : HHSN268200800007C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000040
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85081
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : N01 HC095167
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12015/5
Pays : United Kingdom
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: JYW and RM report research support from Unilever for other projects on fatty acid biomarkers. LCDG reported receiving ad hoc consulting fees from the Life Sciences Research Organization. CH reported receiving fees for a conference from Novartis. IAB reported involvement in a research project partly funded by Unilever. JGR received research grants from Amarin and Astra-Zeneca. DM reported receiving ad hoc honoraria from Bunge, Pollock Institute, and Quaker Oats; ad hoc consulting for Foodminds, Life Sciences Research Organization, Nutrition Impact, Amarin, AstraZeneca, Winston, and Strawn LLP; membership in Unilever North America Scientific Advisory Board; and chapter royalties from UpToDate. SSSM reported receiving an international award and unrestricted grants for meta-analysis work on dairy foods and cardiometabolic diseases from Global and Dutch Dairy Associations. Other authors do not have any conflict of interest to declare.
Références
J Mass Spectrom. 1997 Jan;32(1):81-6
pubmed: 9008871
Prog Lipid Res. 2013 Jan;52(1):15-42
pubmed: 23000367
Am J Clin Nutr. 2007 Jul;86(1):189-97
pubmed: 17616780
JAMA Cardiol. 2016 Oct 1;1(7):745-753
pubmed: 27541681
Am J Clin Nutr. 2011 Jan;93(1):127-42
pubmed: 20980488
Circ Cardiovasc Genet. 2013 Apr;6(2):171-83
pubmed: 23362303
Nat Commun. 2013;4:1528
pubmed: 23443556
J Lipid Res. 1997 Oct;38(10):2012-22
pubmed: 9374124
N Engl J Med. 2010 Nov 18;363(21):2015-26
pubmed: 20929341
PLoS Med. 2016 Jul 19;13(7):e1002094
pubmed: 27434045
PLoS One. 2016 Feb 16;11(2):e0147894
pubmed: 26881936
Diabetes Care. 2014 Feb;37(2):569-86
pubmed: 24459154
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Diabetes. 2003 Mar;52(3):726-33
pubmed: 12606514
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6207-6219
pubmed: 31369090
Am J Clin Nutr. 2013 Mar;97(3):584-96
pubmed: 23364021
Diabetes. 2001 Jan;50(1):69-76
pubmed: 11147797
PLoS Med. 2018 Oct 10;15(10):e1002670
pubmed: 30303968
Cell. 2008 Sep 19;134(6):933-44
pubmed: 18805087
Am J Clin Nutr. 2017 Jun;105(6):1272-1282
pubmed: 28446501
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):231-42
pubmed: 25782093
Am J Clin Nutr. 2014 Sep;100(3):891-900
pubmed: 25057154
Cell Metab. 2014 Nov 4;20(5):703-705
pubmed: 25440051
Prog Lipid Res. 2008 Sep;47(5):348-80
pubmed: 18435934
N Engl J Med. 1993 Jan 28;328(4):238-44
pubmed: 8418404
Lancet Diabetes Endocrinol. 2017 Dec;5(12):965-974
pubmed: 29032079
J Nutr. 2006 Mar;136(3):565-9
pubmed: 16484525
PLoS Med. 2016 Jul 19;13(7):e1002087
pubmed: 27434027
J Clin Invest. 2006 Nov;116(11):3015-25
pubmed: 17053832
JAMA Intern Med. 2016 Aug 1;176(8):1155-66
pubmed: 27357102
J Am Heart Assoc. 2019 Nov 19;8(22):e012881
pubmed: 31711385
Trends Endocrinol Metab. 2011 Jan;22(1):1-8
pubmed: 20889351
Am J Clin Nutr. 2010 Nov;92(5):1214-22
pubmed: 20861175
Circulation. 2008 Sep 30;118(14):1467-75
pubmed: 18794388
Am J Clin Nutr. 2006 Feb;83(2):227-36
pubmed: 16469979
Proc Nutr Soc. 2020 Feb;79(1):30-41
pubmed: 30942685
Diabetes. 2001 Aug;50(8):1771-7
pubmed: 11473037
Nutr Metab Cardiovasc Dis. 2008 Sep;18(7):503-10
pubmed: 18042359
Curr Opin Lipidol. 2008 Jun;19(3):242-7
pubmed: 18460914
Lancet Diabetes Endocrinol. 2014 Oct;2(10):810-8
pubmed: 25107467
Diabetes Care. 2018 Aug;41(8):1732-1739
pubmed: 29844096
Am J Clin Nutr. 2019 Feb 1;109(2):260-268
pubmed: 30721918
Am J Clin Nutr. 2011 Aug;94(2):431-8
pubmed: 21697077
Metabolism. 2014 Jul;63(7):895-902
pubmed: 24814684
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
Nat Med. 2010 Apr;16(4):400-2
pubmed: 20376053
Diabetologia. 2015 Nov;58(11):2533-44
pubmed: 26277381
Am J Clin Nutr. 2003 Jul;78(1):91-8
pubmed: 12816776
Lipids. 2008 Jan;43(1):65-77
pubmed: 18046594
Am J Clin Nutr. 2019 Jun 1;109(6):1527-1534
pubmed: 30997506
Eur J Nutr. 2019 Jul 26;:
pubmed: 31350637
Annu Rev Med. 2012;63:329-43
pubmed: 22034869